CLAIMS

1. Use of camizestrant, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a human patient in need thereof, wherein a therapeutically effective amount of camizestrant, or a pharmaceutically acceptable salt thereof, is to be administered to the human patient, wherein the camizestrant is to be administered in combination with capivasertib, or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the cancer is breast cancer.

3. The use according to claim 1, wherein the cancer is estrogen receptor positive, HER2-negative breast cancer.

4. The use according to claim 1, wherein the cancer is a breast cancer with a mutation in ESR1 or an ESR1-fusion.

5. The use according to claim 1, wherein the cancer is a breast cancer with a mutation in ESR1 that is selected from an E380Q mutation, a Y537S mutation, and a D538G mutation, or an ESR1-CCDC170 fusion.

6. The use according to claim 1, wherein the cancer is a breast cancer with a PI3KCA mutation.

7. The use according to claim 1, wherein the cancer is a breast cancer with a PI3KCA mutation selected from R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L and G1049R.

8. The use according to claim 1, wherein the cancer is a breast cancer with a mutation in ESR1 or an ESR1-fusion or a PI3KCA mutation.

9. The use according to claim 1, wherein the cancer is a breast cancer that has a AKT1 mutation.

10. The use according to claim 1, wherein the cancer is a breast cancer that has a AKT1 mutation and no ESR1 mutation or fusion.

11. The use according to claim 1, wherein the camizestrant is to be administered once daily at a dose of 75mg.

12. The use according to claim 1, wherein the capivasertib is to be administered in at least one cycle comprising 4 days dosing at a dose of 400mg twice daily followed by 3 days with no dosing.

13. The use according to claim 1, wherein the camizestrant is to be administered once daily at a dose of 75mg and wherein the capivasertib is to be administered in at least one cycle comprising 4 days dosing at a dose of 400mg twice daily followed by 3 days with no dosing.

14. The use according to claim 1, wherein a CDK4/6 inhibitor is to be further administered.

15. The use according to claim 1, wherein a CDK4/6 inhibitor is to be further administered, wherein the CDK4/6 inhibitor is selected from palbociclib or a pharmaceutically acceptable salt thereof, ribociclib or a pharmaceutically acceptable salt thereof and abemaciclib or a pharmaceutically acceptable salt thereof.